Waiting For Next Regulatory Shoe To Drop For Takeda's Gout Drug Uloric

FDA already issued a warning based on preliminary data from the CARES outcomes study, but now the final results of the confirmatory trial are in and show higher risk for cardiovascular death for Uloric compared with generic allopurinol.